FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.
What happened
FDA inspected the testing facility from January 15 to January 24, 2025, and found violations of Good Laboratory Practice (GLP) rules for nonclinical laboratory studies of medical devices. The findings included missing daily animal observations, records showing the same staff or equipment used at overlapping times, records completed retroactively, animals reused contrary to protocols, and incomplete tracking of test articles. FDA also found quality assurance audit records did not support reported audits, and it called the company's February 21, 2025 response inadequate.
What FDA found
The study director did not ensure studies followed protocols, experimental data were accurately recorded and verified, or GLP rules were followed.
21 CFR 58.33(a), (b), and (e)The facility lacked procedures to track test article identity and document receipt and distribution of each batch.
21 CFR 58.107(c) and (d)The quality assurance unit did not adequately inspect studies or keep records supporting reported audits, and it missed data problems.
21 CFR 58.35(b)(3)The facility had conflicting SOPs and study directors did not authorize or document deviations from SOPs in raw data.
21 CFR 58.81(a)
What FDA wants
FDA asks the company to promptly correct the violations and provide an adequate response with revised SOPs, training materials, audit and preventive-action plans, and evidence of effectiveness; no response deadline is stated in the letter.
Who should pay attention
- medical device manufacturers whose devices were tested at this lab
- sponsors relying on GLP study reports for FDA submissions
- contract testing labs and quality assurance teams
This is a summary. Read the original letter on fda.gov.